Published in Semin Hematol on January 01, 2011
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood (2012) 1.46
Smoldering multiple myeloma. Blood (2015) 1.03
Three-dimensional Nuclear Telomere Organization in Multiple Myeloma. Transl Oncol (2013) 0.82
Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med (2016) 0.75
Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol (2007) 3.32
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA (2007) 2.51
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol (2011) 2.34
Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer (2007) 2.16
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol (2011) 2.11
Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell (2013) 2.06
Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol (2007) 2.02
Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals. Clin Infect Dis (2012) 2.01
Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer (2009) 2.01
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol (2009) 1.88
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology (2009) 1.80
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood (2008) 1.78
Minimal residual disease: what are the minimum requirements? J Clin Oncol (2014) 1.76
Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood (2013) 1.64
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood (2008) 1.61
Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev (2008) 1.59
Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol (2007) 1.54
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol (2011) 1.51
Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans. Leuk Lymphoma (2011) 1.50
Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica (2009) 1.50
Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum (2008) 1.50
Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr (2010) 1.47
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood (2012) 1.46
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol (2012) 1.46
Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev (2005) 1.45
Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden. Int J Cancer (2012) 1.39
Cancer risk among patients with myotonic muscular dystrophy. JAMA (2011) 1.38
Serum free light chains as predictors of lymphomagenesis in patients with autosomal dominant hyper-immunoglobulin E syndrome (Job's syndrome). Leuk Lymphoma (2012) 1.38
Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology (2008) 1.36
Autoimmunity and lymphomagenesis. Int J Cancer (2009) 1.29
IMWG consensus on maintenance therapy in multiple myeloma. Blood (2012) 1.29
Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer (2010) 1.25
Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica (2010) 1.25
Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst (2010) 1.24
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica (2009) 1.21
Myeloma and second primary cancers. N Engl J Med (2011) 1.20
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica (2009) 1.19
Highly increased familial risks for specific lymphoma subtypes. Br J Haematol (2009) 1.16
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood (2009) 1.15
Chronic immune stimulation and subsequent Waldenström macroglobulinemia. Arch Intern Med (2008) 1.14
Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica (2013) 1.14
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer (2009) 1.12
Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States. J Clin Oncol (2010) 1.11
Cancer incidence among pesticide applicators exposed to permethrin in the Agricultural Health Study. Environ Health Perspect (2008) 1.09
Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood (2010) 1.09
Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem (2011) 1.06
Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Arch Intern Med (2009) 1.06
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma (2013) 1.06
MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med (2012) 1.06
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood (2013) 1.06
Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol (2012) 1.05
Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol (2009) 1.04
Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica (2009) 1.03
Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients. Cancer Epidemiol Biomarkers Prev (2010) 1.03
Bortezomib to treat the TEMPI syndrome. N Engl J Med (2012) 1.02
Risks of cancer among a cohort of 23,935 men and women with osteoporosis. Int J Cancer (2008) 1.00
High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood (2004) 1.00
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood (2003) 1.00
Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol (2011) 1.00
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med (2012) 0.98
Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom (2010) 0.98
A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood (2012) 0.97
Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma (2011) 0.97
Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc (2010) 0.96
Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol (2009) 0.96
Chronic lymphocytic leukaemia genetics overview. Br J Haematol (2007) 0.95
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica (2011) 0.94
Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data. Ann Epidemiol (2013) 0.94
A population-based assessment of mortality and morbidity patterns among patients with thymoma. Int J Cancer (2010) 0.93
No familial aggregation in chronic myeloid leukemia. Blood (2013) 0.92
Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood (2011) 0.92
Prevalence of monoclonal B-cell lymphocytosis: a systematic review. Cytometry B Clin Cytom (2010) 0.92
Plasma cell neoplasms in US solid organ transplant recipients. Am J Transplant (2013) 0.92
Circulating cytokine levels, Epstein-Barr viremia, and risk of acquired immunodeficiency syndrome-related non-Hodgkin lymphoma. Am J Hematol (2011) 0.91
Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia. Clin Lymphoma Myeloma (2009) 0.91
Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma". Leuk Lymphoma (2013) 0.90
Increased levels of circulating cytokines with HIV-related immunosuppression. AIDS Res Hum Retroviruses (2011) 0.90
Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity. Cancer (2013) 0.90
Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. Blood (2007) 0.90
A method to visualize and adjust for selection bias in prevalent cohort studies. Am J Epidemiol (2011) 0.90
Timing of births and endometrial cancer risk in Swedish women. Cancer Causes Control (2009) 0.89
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC Med Genet (2010) 0.88
Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas. European J Clin Med Oncol (2010) 0.88
Hodgkin lymphoma among US solid organ transplant recipients. Transplantation (2010) 0.88
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn (2010) 0.87
Survival patterns among lymphoma patients with a family history of lymphoma. J Clin Oncol (2008) 0.86
Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation (2013) 0.86
Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma (2009) 0.86
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood (2011) 0.86